Dutch Atherosclerosis Society

Prof. dr. A.J. van Zonneveld 

PERSONAL DATA

NAME: Anton Jan van Zonneveld

OFFICE ADDRESS: A. J. van Zonneveld, Ph.D
Department of Nephrology, C3-P
Leiden University Medical Center
Albinusdreef 2, 2333 ZA Leiden
The Netherlands
tel: +31 071-5262148/5196
fax: +31 071-5248118
e-mail: a.j.vanzonneveld@lumc.nl

DATE OF BIRTH June 12, 1957

CITIZENSHIP Dutch



EDUCATION - POSITIONS

1969 - 1975 Secondary school: Atheneum B, Christelijk Lyceum dr. W.A. Visser’t Hooft, Leiden

1975 - 1982 Doctoral degree at the Rijks Universiteit Leiden in Biology (B4), main subjects: molecular genetics and biochemistry

1982 - 1986 Appointment at the Department of Moleculair Biology of the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB), Amsterdam. Research program on “the structure and function of human tissue-type plasminogen activator”

1986 Presentation of a thesis, entitled: “Structure and function of human tissue-type plasminogen activator” at the University of Amsterdam. Promotor Prof. dr. P. Borst , Co-promotor dr. H. Pannekoek

1986 - 1988 Recipient of a “Long Term Fellowship” from the European Molecular Biology Organisation (EMBO) for a study on “The transcriptional regulation of the plasminogen activator inhibitor-1 gene” in the Laboratory of dr. D.J. Loskutoff at the Research Institute of Scripps Clinic, La Jolla, California, USA

1988 - 1993 Post-doctoral fellow at the Department of Moleculair Biology of the Central Laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB), Amsterdam.

1993 - 1998 Appointment as a Fellow of the Royal Netherlands Academy of Arts and Sciences (KNAW) at the Department of Biochemistry, Faculty of Medicine, University of Amsterdam. Subject: “Identification of genes involved in atherosclerosis that are expressed by the endothelial cell”

1998 Associate professor at the Department of Biochemistry, Faculty of Medicine, Academic Medical Center Amsterdam.

1998 - 2001 Managing Director Cardiovascular Research Crucell Belgium NV.

2001 – 2003 Head of the Laboratory for Vascular Medicine, University Medical Center, Utrecht

2003 - 2004 Professor of Experimental Vascular Medicine at the University of Utrecht
Member of the management team of the department of Internal Medicine

Feb 2004 Professor of Experimental Vascular Medicine at the department of Nephrology, Leiden University Medical Center


SCIENTIFIC COMMITTEES:


Member of the NWO working committee on Thrombosis and Hemostasis

Member of the Scientific Programme Committee of the XVII Congress of the International Society on Thrombosis and Haemostasis (Washington, USA, august 14-21, 1999)

Board member of the Dutch Atherosclerosis Society (DAS)


HONOURS

Xth International Congress on Fibrinolysis. “Award for an outstanding contribution by a scientist under 35 years” 1988


GRANTS AQUIRED:


1986 Regulation of the fast-acting plasminogen activator inhibitor (PAI-1) gene in endothelial cells. EMBO “Long Term Fellowship”

1992 Identification of “atherosclerotic” genes, expressed by activated vascular endothelial cells. NWO/NHS “opstart subsidie”.

1992 The role of specific receptors for complexes between tissue-type plasminogen activator (T-PA) and plasminogen activator inhibitor 1 (PAI-1) in the regulation of endogenous fibrinolysis. NWO, PC 902-26-128

1993 Identification of genes involved in atherosclerosis that are expressed by the endothelial cell, Royal Netherlands Academy of Arts and Sciences (KNAW)

1994 Center grant application atherosclerosis for the Netherlands Heart Foundation.
Molecular Cardiology Program (Participant)

1995 The role of low density lipoprotein receptor-related protein (LRP) in the pathogenesis of atherosclerosis. NWO PC 902-26-175

1997 Lipases and receptors as determinants of lipoprotein and energy metabolism. Coordinator: Prof. T. Olivecrona, Biomed 2; Reinforced Concertation (Participant).

2002 Genetic and functional analysis of endothelial progenitor cells in ischemic vascular disease (NHS 2002B157)

2002 Improved tissue engineering of bone by combining advanced cell technology and vasculogenesis (STW)